A Prospective Observational Study to Evaluate the Effectiveness of Deucravacitinib in Patients With Moderate Plaque Psoriasis in Real-World Settings in China (ADMIRE)
Latest Information Update: 06 Feb 2025
At a glance
- Drugs Deucravacitinib (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms ADMIRE
- Sponsors Bristol-Myers Squibb
Most Recent Events
- 03 Feb 2025 Status changed from not yet recruiting to recruiting.
- 16 Dec 2024 Planned initiation date changed from 1 Jan 2025 to 10 Feb 2025.
- 25 Jul 2024 New trial record